Do analysts recommend BGMS or NXTC?

NextCure has a consensus price target of $23.00, suggesting a potential upside of 652.86%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is BGMS or NXTC more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% NextCure N/A -186.96% -124.62%

Does the media favor BGMS or NXTC?

In the previous week, NextCure had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 4 mentions for NextCure and 3 mentions for Cyclacel Pharmaceuticals. NextCure's average media sentiment score of 0.03 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend VYNE or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend HOWL or BGMS?

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 797.13%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts prefer GNTA or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, GNTA or BGMS?

Cyclacel Pharmaceuticals has higher revenue and earnings than Genenta Science. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Cyclacel Pharmaceuticals $750K 16.34 -$3M -$4.54 N/A

Is GNTA or BGMS more profitable?

Genenta Science's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate BGMS or KZIA?

Novogen has a consensus price target of $21.00, indicating a potential upside of 87.23%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, BGMS or KZIA?

Cyclacel Pharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 16.34 -$3M -$4.54 N/A Novogen $42K 441.43 -$13.41M N/A N/A

Is BGMS or KZIA more profitable?

Novogen's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% Novogen N/A N/A N/A

Does the media favor BGMS or KZIA?

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 1 mentions for Novogen. Novogen's average media sentiment score of 0.94 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Novogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cyclacel Pharmaceuticals (BGMS) Competitors

$2.16 +1.11 (+104.25%)

As of 10:16 AM Eastern

Compare

BGMS vs. NXTC, VYNE, HOWL, GNTA, and KZIA

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? MarketBeat compares Cyclacel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclacel Pharmaceuticals include NextCure (NXTC), VYNE Therapeutics (VYNE), Werewolf Therapeutics (HOWL), Genenta Science (GNTA), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.

How does Cyclacel Pharmaceuticals compare to NextCure?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, NextCure had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 4 mentions for NextCure and 3 mentions for Cyclacel Pharmaceuticals. NextCure's average media sentiment score of 0.03 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Cyclacel Pharmaceuticals has higher revenue and earnings than NextCure. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	16.34	-$3M	-$4.54	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

NextCure has a consensus price target of $23.00, suggesting a potential upside of 652.86%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cyclacel Pharmaceuticals' return on equity of -51.21% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
NextCure	N/A	-186.96%	-124.62%

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 11.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NextCure beats Cyclacel Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Cyclacel Pharmaceuticals has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$454K	47.90	-$26.48M	-$0.38	N/A
Cyclacel Pharmaceuticals	$750K	16.34	-$3M	-$4.54	N/A

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.87 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VYNE Therapeutics	Very Positive
Cyclacel Pharmaceuticals	Neutral

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Cyclacel Pharmaceuticals' return on equity of -51.21% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats VYNE Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 797.13%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 3 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.04 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Werewolf Therapeutics. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	10.81	-$60.82M	-$1.24	N/A
Cyclacel Pharmaceuticals	$750K	16.34	-$3M	-$4.54	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Werewolf Therapeutics beats Cyclacel Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Very Positive
Cyclacel Pharmaceuticals	Neutral

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genenta Science has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

Genenta Science's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than Genenta Science.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Cyclacel Pharmaceuticals	$750K	16.34	-$3M	-$4.54	N/A

Summary

Genenta Science beats Cyclacel Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Novogen?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Novogen (NASDAQ:KZIA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Novogen's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Novogen	N/A	N/A	N/A

Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market. Comparatively, Novogen has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 1 mentions for Novogen. Novogen's average media sentiment score of 0.94 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cyclacel Pharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	16.34	-$3M	-$4.54	N/A
Novogen	$42K	441.43	-$13.41M	N/A	N/A

Novogen has a consensus price target of $21.00, indicating a potential upside of 87.23%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Novogen beats Cyclacel Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGMS vs. The Competition

Export

Metric	Cyclacel Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$12.38M	$993.29M	$4.31B	$12.24B
Dividend Yield	N/A	4.84%	7.93%	5.31%
P/E Ratio	-0.49	1.49	21.79	24.03
Price / Sales	16.34	130.75	220.75	92.16
Price / Cash	N/A	20.06	53.68	55.53
Price / Book	1.59	8.00	29.16	6.57
Net Income	-$3M	-$3.91M	$109.80M	$337.00M
7 Day Performance	101.82%	-1.13%	-1.43%	-1.24%
1 Month Performance	115.53%	66.13%	3.23%	2.42%
1 Year Performance	N/A	110.19%	14.51%	31.55%

Cyclacel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGMS Cyclacel Pharmaceuticals	0.5504 of 5 stars	$2.22 +109.4%	N/A	N/A	$12.38M	$750K	N/A	14	News Coverage High Trading Volume
NXTC NextCure	3.4623 of 5 stars	$6.20 -3.1%	$23.00 +271.0%	-43.8%	$23.12M	N/A	N/A	90	News Coverage
VYNE VYNE Therapeutics	1.1595 of 5 stars	$0.68 -0.7%	N/A	-32.8%	$22.91M	$570K	N/A	30	Positive News
HOWL Werewolf Therapeutics	3.749 of 5 stars	$0.45 -1.3%	$3.75 +733.3%	-67.2%	$22.16M	$1.88M	N/A	40	Gap Up
GNTA Genenta Science	1.0892 of 5 stars	$1.03 +15.1%	N/A	-55.0%	$21.11M	N/A	N/A	7	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. NXTC, VYNE, HOWL, GNTA, and KZIA

How does Cyclacel Pharmaceuticals compare to NextCure?

Summary

How does Cyclacel Pharmaceuticals compare to VYNE Therapeutics?

Summary

How does Cyclacel Pharmaceuticals compare to Werewolf Therapeutics?

Summary

How does Cyclacel Pharmaceuticals compare to Genenta Science?

Summary

How does Cyclacel Pharmaceuticals compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. NXTC, VYNE, HOWL, GNTA, and KZIA

How does Cyclacel Pharmaceuticals compare to NextCure?

Does the media favor BGMS or NXTC?

Which has more risk & volatility, BGMS or NXTC?

Which has preferable valuation and earnings, BGMS or NXTC?

Do analysts recommend BGMS or NXTC?

Is BGMS or NXTC more profitable?

Do institutionals and insiders hold more shares of BGMS or NXTC?

Summary

How does Cyclacel Pharmaceuticals compare to VYNE Therapeutics?

Which has preferable earnings and valuation, VYNE or BGMS?

Does the media prefer VYNE or BGMS?

Which has more risk and volatility, VYNE or BGMS?

Do analysts recommend VYNE or BGMS?

Is VYNE or BGMS more profitable?

Do insiders & institutionals hold more shares of VYNE or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Werewolf Therapeutics?

Do analysts recommend HOWL or BGMS?

Is HOWL or BGMS more profitable?

Does the media prefer HOWL or BGMS?

Which has more volatility & risk, HOWL or BGMS?

Which has better valuation & earnings, HOWL or BGMS?

Do institutionals & insiders hold more shares of HOWL or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Genenta Science?

Do analysts prefer GNTA or BGMS?

Does the media prefer GNTA or BGMS?

Do insiders & institutionals hold more shares of GNTA or BGMS?

Which has more volatility & risk, GNTA or BGMS?

Is GNTA or BGMS more profitable?

Which has preferable valuation and earnings, GNTA or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Novogen?

Do institutionals & insiders have more ownership in BGMS or KZIA?

Is BGMS or KZIA more profitable?

Which has more volatility and risk, BGMS or KZIA?

Does the media favor BGMS or KZIA?

Which has stronger valuation and earnings, BGMS or KZIA?

Do analysts rate BGMS or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools